John Wen-Cheng Chang
Overview
Explore the profile of John Wen-Cheng Chang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
857
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chung H, Kondoh C, Bae W, Tamada S, Matsubara N, Lee H, et al.
Jpn J Clin Oncol
. 2025 Jan;
PMID: 39815637
Background: The phase 3 open-label KEYNOTE-426 study demonstrated that first-line pembrolizumab plus axitinib improved overall survival (OS) and progression-free survival (PFS) versus sunitinib for metastatic renal cell carcinoma (mRCC) in...
2.
Chen C, Hung S, Chang J, Yang C, Ma D, Teng Y, et al.
Nat Commun
. 2024 Dec;
15(1):10733.
PMID: 39737932
Immune checkpoint inhibitors (ICI) represent new anticancer agents and have been used worldwide. However, ICI can potentially induce life-threatening severe cutaneous adverse reaction (SCAR), such as Stevens-Johnson syndrome/toxic epidermal necrolysis...
3.
Chen C, Wang C, Lu C, Chen W, Zhou B, Chu C, et al.
J Allergy Clin Immunol Pract
. 2024 Nov;
13(1):143-154.e10.
PMID: 39505105
Background: Osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), shows superior lung cancer treatment efficacy. However, osimertinib-induced severe hypersensitivity, including Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), is frequently...
4.
Hsu P, Chang J, Chiu L, Yang C, Kuo S, Fang Y, et al.
Clin Transl Oncol
. 2024 Sep;
PMID: 39317868
Background And Objectives: Genomic alterations after resistance to osimertinib therapy in advanced T790M-mutated non-small cell lung cancer (NSCLC) are complex and poorly understood. In this study, we aimed to detect...
5.
Cheng Y, Spigel D, Cho B, Laktionov K, Fang J, Chen Y, et al.
N Engl J Med
. 2024 Sep;
391(14):1313-1327.
PMID: 39268857
Background: Adjuvant therapy with durvalumab, with or without tremelimumab, may have efficacy in patients with limited-stage small-cell lung cancer who do not have disease progression after standard concurrent platinum-based chemoradiotherapy....
6.
Hung L, Huang C, Tung K, Chen J, Huang W, Hsu C, et al.
J Formos Med Assoc
. 2024 Sep;
PMID: 39244401
Background: This retrospective study analyzed tumor tissue profiling data to assess the potential of comprehensive genomic profiling (CGP) for patient care across diverse solid tumors. Material And Methods: Patients with...
7.
Hsu H, Chung W, Lin Y, Yang T, Chang J, Hsieh C, et al.
Allergol Int
. 2024 Apr;
73(4):580-586.
PMID: 38594174
Background: Oxaliplatin is commonly used to treat gastrointestinal malignancies. However, its applications are limited due to potential adverse drug reactions (ADRs), particularly severe anaphylactic shock. There is no method to...
8.
Chang J, Hsieh J, Tsai C, Chiu H, Lin Y, Wu C, et al.
Biomed J
. 2024 Jan;
47(5):100698.
PMID: 38280521
Background: There is currently no well-accepted consensus on the association between gut microbiota and the response to treatment of immune checkpoint inhibitors (ICIs) in patients with advanced cancer. Methods: Fecal...
9.
Wei H, Lai Y, Lin G, Lin C, Chang Y, Chang J, et al.
Diabetol Metab Syndr
. 2024 Jan;
16(1):26.
PMID: 38254155
Background: Immune checkpoint inhibitors (ICI) are promising treatment options for various cancers. However, their use is associated with immune-related adverse events (irAEs), including ICI-induced diabetes mellitus (ICI-DM). This study aimed...
10.
Shih J, Luo Y, Chang G, Chang J, Wang C, Yang T, et al.
J Formos Med Assoc
. 2024 Jan;
123(8):875-881.
PMID: 38195317
Background: Lorlatinib is a brain-penetrant, third-generation anaplastic lymphoma kinase (ALK) inhibitor indicated for ALK-positive metastatic non-small cell lung cancer (NSCLC). In a global phase II study, patients who experience disease...